A scientist from the University of the West of England has been awarded a grant of almost £25,000 from Bowel Cancer UK to understand why some patients with rectal cancer don’t respond well to certain treatments and look for new ways to improve its chance of success.
Dr Alex Greenhough will be studying proteins that are found in bowel cancer cells to find out if they affect how patients respond to chemotherapy and radiotherapy. In collaboration with Mr Adam Chambers and Prof Ann Williams from the University of Bristol, they hope to discover how subtle differences in these proteins might help them to which patients will respond best to this type of treatment.
Knowing which patients are likely to respond well to chemotherapy and radiotherapy means this treatment can be offered to those who would most benefit from it. Most importantly, patients will be spared from the side effects of a treatment that simply won’t work for them.
This award is part of Bowel Cancer UK’s investment of over £1.3 million pounds to support research with the greatest benefits for those at risk and affected by the disease.
Bowel cancer is the second biggest cancer killer in the UK, however it shouldn’t be because it is treatable and curable especially if diagnosed early.
Dr Alex Greenhough at the University of the West of England, says: “We are incredibly grateful for this funding from Bowel Cancer UK, which will give us a fantastic opportunity to make important progress towards better understanding patient responses to chemoradiotherapy and ultimately improve clinical outcomes.”
Dr Lisa Wilde, Director of Research and External Affairs at Bowel Cancer UK, says: “We are delighted to invest in Dr Greenhough’s research. This important work will support our commitment to invest in high quality, innovative and creative solutions to help lead a step change in the number of people surviving bowel cancer.”